• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits

    11/5/25 4:31:15 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email
    false 0001641631 0001641631 2025-11-03 2025-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): November 3, 2025

     

    Beyond Air, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-38892   47-3812456

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    900 Stewart Avenue, Suite 301

    Garden City, NY 11530

    (Address of Principal Executive Offices and Zip Code)

     

    (516) 665-8200

    Registrant’s Telephone Number, Including Area Code

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $.0001 per share   XAIR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    Equity Purchase Agreement

     

    On November 4, 2025, Beyond Air, Inc., (the “Company”) entered into an equity purchase agreement (the “Purchase Agreement”) with Streeterville Capital, LLC (“Streeterville”) for the purchase of up to $20 million of the Company’s shares of common stock. In connection with the Purchase Agreement, the Company and Streeterville entered into a Registration Rights Agreement (the “Registration Rights Agreement”), pursuant to which the Company agreed to file with the Securities and Exchange Commission a registration statement (the “Registration Statement”) covering the resale of the shares by November 24, 2025.

     

    Pursuant to the Purchase Agreement, upon effectiveness of the Registration Statement and so long as there is no balance outstanding on the Note (as defined below), the Company shall have the right, but not the obligation, to direct Streeterville, by its delivery to Streeterville of a put notice from time to time during a period of up to two years, to purchase shares of common stock (i) in a minimum amount not less than $25,000, and (ii) in a maximum amount up to the median daily trading volume of the common stock during the five trading days immediately preceding delivery of the put notice, or such other greater amount mutually agreed upon by the parties; provided, however, that the number of put shares shall not exceed the beneficial ownership limitation, which shall be 4.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable pursuant to a put notice (the “Beneficial Ownership Limitation”). The purchase price for each put shall be 96% of the lowest daily volume weighted average price of the common stock during the four consecutive trading day period commencing on the trading day immediately following delivery of a put notice. On any trading day during which the Registration Statement remains effective and the Note remains outstanding and (i) any trading price of the common stock is at least 5% greater than the current Nasdaq minimum price as defined under Nasdaq Rule 5635(d) (the “Nasdaq Minimum Price”) or (ii) the total dollar trading volume has reached $750,000.00, Streeterville may elect to purchase shares of common stock up to the Beneficial Ownership Limitation at a purchase price equal to 85% of the Nasdaq Minimum Price, subject to a floor of $0.39 per share. The aggregate purchase price for these shares shall be offset by an equal amount outstanding under the Note. In no event shall the Company effect any issuances under the Purchase Agreement in violation of Nasdaq’s 19.99% limitation unless the Company’s stockholders have approved the issuance of common shares in excess of the 19.99% limitation in accordance Nasdaq Rule 5635(d) or the applicable Purchase Price equals or exceeds the Nasdaq Minimum Price on the effective date of the Purchase Agreement.

     

    The foregoing descriptions of the terms and conditions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by the full text of the agreements, which are filed as Exhibit 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Amended and Restated Loan and Security Agreement; Waiver

     

    As previously disclosed, on November 1, 2024, the Company entered into a loan and security agreement (the “Original Loan and Security Agreement”) with certain lenders including its Chief Executive Officer Steven Lisi and director Robert Carey (collectively, the “Lender”), that provided for a $11,500,000 loan and the issuance of warrants to purchase up to an aggregate of 757,975 shares of common stock to Mr. Lisi and Mr. Carey (the “2024 Warrants”). On November 3, 2025, the Company and the Lender amended and restated the Original Loan and Security Agreement (as amended, the “Amended and Restated Loan and Security Agreement”) to provide for an additional $2,000,000 term loan to the Company and the issuance of new five-year warrants to Mr. Carey to purchase up to 512,821 shares of common stock at an exercise price of $1.95 per share (the “Supplemental Warrants”).

     

     

     

     

    Concurrently, the parties entered into a Waiver Agreement (the “Waiver”), pursuant to which the Lender consented to the Company’s issuance of the Note in exchange for reducing the exercise price of the 2024 Warrants to $1.95 per share.

     

    The foregoing descriptions of the Amended and Restated Loan and Security Agreement, Supplemental Warrants and the Waiver do not purport to be complete and are qualified in their entirety by the full text of the Amended and Restated Loan and Security Agreement, the Form of Supplemental Warrant and the Waiver, which are filed as Exhibit 10.3, 4.1 and 10.4 to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    Also on November 4, 2025, the Company entered into and closed on a note purchase agreement (the “Note Purchase Agreement”) with Streeterville, which provided for the issuance of a secured promissory note in the principal amount of $12,050,000 (the “Note”). The Company agreed to pay $50,000 to Streeterville to cover Streeterville’s transaction costs, resulting in the Company receiving net proceeds of $12,000,000.

     

    The principal amount of the Note is due 24 months following the date of issuance. Interest will accrue at the rate of 15% per annum, with no interest accruing for the first 12 months following issuance; provided however, that Streeterville is guaranteed 12 months of interest, or $1,800,000 even if the note is redeemed or prepaid prior to the maturity date. If the Note is outstanding within 90 days of issuance, a one-time monitoring fee will be added to the outstanding balance of the note in the amount of the outstanding balance divided by 0.85 less the outstanding balance. The monitoring fee will be credited back to the Company on a pro-rata basis if the Company makes a cash payment and either (i) the 200-day median trading volume is less than $1,000,000 or (ii) the market capitalization of the Company is below $50,000,000. Streeterville shall have the right to redeem the Note commencing on the 12-month anniversary of the issuance date, or six months from the issuance date if either (i) the Registration Statement has not been declared effective or (ii) the Company is unable for any reason to issue common stock under the Purchase Agreement. The Company may prepay the note in part or in full at any time without penalty. While the Note is outstanding, the Company may not issue new debt or, subject to certain exceptions, enter into variable rate transactions.

     

    At any time following the occurrence of a Major Trigger Event or Minor Trigger Event (each as defined in the Note), the Lender may, upon prior written notice to the Company, increase the outstanding balance of the Note by 9% for each occurrence of any Major Trigger Event and 4% for each occurrence of any Minor Trigger Event (the “Trigger Effect”), provided that the Trigger Effect may only be applied three times with respect to Major Trigger Events and three times with respect to Minor Trigger Events. Subject to certain exceptions described below, if the Company fails to cure a Trigger Event within five trading days following the date of transmission of a written demand notice by the Lender, the Trigger Event will automatically become an Event of Default (as defined in the Note). Following the occurrence of any Event of Default, the Lender may, upon written notice to the Company, (i) accelerate the Note, with the outstanding balance of the Note following application of the Trigger Effect (the “Mandatory Default Amount”) becoming immediately due and payable in cash, and (ii) cause interest on the outstanding balance of the Exchange Note beginning on the date the applicable Event of Default occurred to accrue at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law. Notwithstanding the foregoing, upon the occurrence of certain Trigger Events related to bankruptcy or insolvency, immediately and without notice, an Event of Default will be deemed to have occurred and the outstanding balance of the Exchange Note as of the date of the occurrence of such Bankruptcy-Related Trigger Event will become immediately and automatically due and payable in cash at the Mandatory Default Amount.

     

    $6,000,000 of the net proceeds from the Note were wired to the Company and $6,000,000 were sent to a deposit account owned and controlled by the Company’s new wholly-owned subsidiary XAIR Holdings, LLC (“Xair Holdings”). The Note is secured by a deposit account control agreement (the “DACA”) with an initial cash collateral requirement of $6,000,000, which requirement will be reduced by $0.50 for every $1.00 of principal repaid on the outstanding balance for the first $3,000,000 million repaid, and further reduced by $0.75 for every $1.00 repaid thereafter. Once the balance of the cash collateral account is $1,000,000 or less, the collateral requirement shall terminate and the Company may withdraw the remaining funds at its discretion. In addition to the DACA, the Note is secured by (i) a guaranty from XAIR Holdings, LLC (the “XAIR Holdings Guaranty”), (ii) a guaranty from certain foreign subsidiaries (the “Foreign Subsidiary Guaranty”), and (iii) various security agreements and intellectual property pledges as detailed in Exhibits 10.6 through 10.12.

     

     

     

     

    The foregoing descriptions of the terms and conditions of the Note Purchase Agreement, the Note, the XAIR Holdings Guaranty, the Foreign Subsidiary Guaranty and the related transaction documents are qualified in their entirety by the full text of such documents, which are filed as Exhibits 10.5, 4.2, 10.6, 10.7, 10.8 10.9, 10.10, 10.11 and 10.12, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The information in Item 1.01 is hereby incorporated herein by reference. The shares of common stock issuable under the Purchase Agreement and the Supplemental Warrants (and the shares of common stock underlying the Supplemental Warrants) were not registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered pursuant to an exemption from the registration requirements of the Securities Act provided under Section 4(a)(2) of the Securities Act.

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Repricing of Options.

     

    On November 4, 2025, the Board approved a one-time stock option repricing of 726,618 options (“Option Repricing”), effective November 4, 2025. The repricing was undertaken in accordance with, and as permitted by, the Company’s Amended 2013 Plan. Pursuant to the Option Repricing, all options granted pursuant to the Amended 2013 Plan that are held by Company Board members, officers, and employees expected to continue providing services to the Company were repriced, to the extent such options had an exercise price in excess of $1.95, the closing price per share of the Common Stock as reported on The Nasdaq Stock Market on November 3, 2025. All such options were repriced such that the exercise price per share was reduced to $1.95.

     

    The following options held by the Company’s named executive officers and non-employee directors were included in the Option Repricing:

     

    Name and Position  Number of Option Shares   Exercise Price Range of Original Options 
    Steven Lisi, Chief Executive Officer and Chairman of the Board   195,000    $5.892 - $10.80 
    Robert Carey, Director   21,802    $5.892 - $10.80 
    Erick Lucera, Director   14,252    $5.892 - $10.80 
    Yoori Lee, Director   14,004    $5.892 - $10.80 
    Bill Forbes, Director   13,652    $5.892 - $10.80 
    Douglas Larson, Chief Financial Officer   43,250    $5.892 - $10.80 
    Mike Gaul, Chief Operating Officer   53,250    $5.892 - $10.80 
    Robert Goodman, Director   3,750    $2.45 

     

    The Board approved the Option Repricing following consideration of the Company’s retention policies, the competitive market for key talent, the alignment of employee and stockholder interests, and the overall effectiveness of the Company’s equity incentive program.

     

    Item 8.01. Other Events.

     

    On November 5, 2025, the Company issued a press release announcing that it has entered into financing agreements with Streeterville, providing up to $32 million in total potential proceeds. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference into this Item 8.01.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    4.1   Form of Supplemental Warrant
    4.2   Secured Promissory Note
    10.1   Equity Purchase Agreement
    10.2   Registration Rights Agreement
    10.3   Amended and Restated Loan Agreement
    10.4   Waiver
    10.5   Note Purchase Agreement
    10.6   XAIR Holdings Guaranty
    10.7   Foreign Subsidiary Guaranty
    10.8   Company Security Agreement
    10.9   Company IP Security Agreement
    10.10   BA Israel Security Agreement
    10.11   BA Israel IP Security Agreement
    10.12   Pledge Agreement
    99.1   Press Release of Beyond Air, Inc., dated as of November 5, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BEYOND AIR, Inc.
       
    Date: November 5, 2025 By: /s/ Steven A. Lisi
      Name: Steven A. Lisi
      Title Chief Executive Officer

     

     

     

    Get the next $XAIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    7/17/2025$11.00Buy
    D. Boral Capital
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Beyond Air Inc.

    S-1/A - Beyond Air, Inc. (0001641631) (Filer)

    12/11/25 5:21:02 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    12/11/25 5:16:33 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    11/28/25 1:05:53 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

    BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early sta

    4/1/25 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

    First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ:XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round.

    3/24/25 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

    The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an imm

    12/3/24 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lee Yoori

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:10 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Operating Officer Gaul Michael A.

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:07 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Carey Robert

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/7/25 4:05:31 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air downgraded by BTIG Research

    BTIG Research downgraded Beyond Air from Buy to Neutral

    6/25/24 8:04:46 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Beyond Air with a new price target

    Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

    7/28/23 7:37:57 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

    Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

    6/1/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

    HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

    5/17/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

    Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures As a board-certified pediatric pulmonologist, Dr. Colin has been an active member of Beyond Air's Scientific Advisory Board since 2013 Dr. Colin has participated in over 20 clinical trials, including studies sponsored by the National Institutes of Health, Genentech, GlaxoSmithKline, and the Cystic Fibrosis Foundation's Therapeutic Development Network GARDEN CITY, N.Y., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a c

    12/1/21 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

    SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    10/9/24 1:35:29 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    10/3/24 3:09:56 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    3/7/24 12:29:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Financials

    Live finance-specific insights

    View All

    Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

    10/29/24 4:22:08 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

    LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

    6/28/22 4:10:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

    GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4

    6/14/22 4:30:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care